Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The first-in-human trial initiated last year in healthy adults studied single and multiple doses of NaQuinate. The primary objective was to assess the safety, tolerability and pharmacokinetics.
Lead Product(s): NaQuinate
Therapeutic Area: Musculoskeletal Product Name: NaQuinate
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 26, 2020
Details:
NaQuinate synergized the body’s normal response to loading to generate significant increases in cortical bone mass (increased cross sectional area, reductions in cortical porosity) and J-score (predictor of bone strength) compared to loading alone.
Lead Product(s): NaQuinate
Therapeutic Area: Musculoskeletal Product Name: Osteopura
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020